PLX – PAD for Peripheral Artery Disease

Pluristem’s first product, PLX - PAD, has been developed as a non-personalized (allogeneic) product intended to treat the limb ischemia from Peripheral Artery Disease (PAD). PAD is a chronic disease that progressively restricts blood flow in the limbs and can lead to serious medical complications. This disease is often associated with other clinical conditions, including hypertension, cardiovascular disease, hyperlipidemia, diabetes, obesity and stroke.  Critical Limb Ischemia (CLI) is used to describe patients with chronic ischemia induced pain, ulcers, tissue loss or gangrene in the limb. CLI represents the end stage of PAD patients who need comprehensive treatment by vascular surgery or a vascular specialist. In contrast to coronary and cerebral artery disease, Peripheral Artery Disease (PAD) remains an under-appreciated condition that, despite being serious and extremely prevalent, is rarely diagnosed and even less frequently treated. Consequently, mortality in PAD patients exceeds that of patients with myocardial infarction and stroke; indeed only mortality due to colorectal cancer outweighs that of PAD.

The Market for PLX-PAD

In the US alone, it is estimated that 8-12 million people suffer from limb ischemia.

Industry experts have estimated that the therapeutics used in the treatment of limb ischemia market is $4 Billion.

PLX-PAD is injected intramuscularly (IM) into the patient’s Limb to improve blood flow.

Scientists administered Pluristem’s proprietary PLX-PAD cells in vivo to mice whose hind legs were rendered ischemic using standard industry methodologies. Post-treatment evaluation using Doppler technology indicated revascularization of the limb treated with PLX-PAD cells but not in those that were not treated with PLX-PAD.  Additionally, histological examination of the tissues treated with PLX-PAD showed a significant number of new blood vessels (neovascularity).

PLX-PAD White Paper - click here